|[January 03, 2014]
Dohmen Announces the Acquisition of Three Technology Companies; Red Arrow, Clinical Path Consulting (CPC) and ChemWare
MILWAUKEE --(Business Wire)--
CEO Cynthia (Dohmen) LaConte announced today that Dohmen
has acquired three technology companies; Red
Arrow Labs, Clinical
Path Consulting and ChemWare.
Founder of two of the companies, Mark Grosskopf will join Dohmen as the
CIO of Dohmen
Life Science Services and will continue to serve as president of all
three companies going forward.
LaConte said Dohmen began searching for best practice technology
companies to expand its offering to clients in the areas of applications
development, data analytics, consulting services and hosting. "Our life
science and healthcare clients are increasingly interested in using
technology to connect with and empower healthcare consumers; in
particular, through the growing use of analytics and mobile
LaConte added that the companies' shared values and unique mix of
services played a key role in Dohmen's decision to move forward with the
acquisitions. "We wanted to bring valuable new skills to our clients,
and these companies will do that. Red
Arrow designs and develops unique applications, Clinical
Path Consulting provides regulatory and IT advisory services
to healthcare providers, and ChemWare
offers critical information management solutions to the laboratory
market. But we also wanted to find that new capability rooted in a
common culture; one that operates from a place of purpose and trust."
Grosskopf said he shares LaConte's enthusiasm regarding the companies'
blend of shared values and purpose. "It's exciting to join forces with a
solid, privately held company that shares our goal of leveraging
technology to create efficiencies within healthcare while making a real
difference in peoples' lives by improving the quality of their care."
Founded in 1858, Dohmen is an outsourced services company dedicated to
improving the lives of others by supplying the treatments and tools they
need to live healthier lives.
As the trusted partner to more than 600 BioPharma and MedTech
innovators, through DLSS, Dohmen powers start-up, mid-tier and Fortune
500 companies with support services that span the commercialization
continuum from pre-approval regulatory consulting to in-home patient
services. Privately held and conflict free, Dohmen is uniquely
positioned to propel personalized healthcare for life science innovators
[ Back To TMCnet.com's Homepage ]